| Name | Title | Contact Details |
|---|
HPI redefines what is possible with self-funded health plans. As a third-party administrator, we partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each clients needs and population. Our solutions give employers greater cost transparency and control, while elevating the member experience.
Franklin Products, inc. was founded in 1992 to fill a niche in the marketplace for high quality fluid bed dryer exhaust filters at highly competitive price points for the pharmaceutical industry. Successes in the pharmaceutical industry led to rapid growth into other industries such as food production and chemical manufacturing. All markets where the best quality product is required to do the job!
MACC Investment Group will endeavor to re-energize portfolio brands by providing consistent supportive leadership. We hold our internal support teams accountable to the task of delivering on a mission that supports improving guest transactions concurrent with growing market share. We will develop and coach behaviors that drive performance while holding our corporate team accountable in a business environment that rewards and celebrates improved diligence and fiscal responsibility.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.